Similar articles

• Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response.

  Aronson JK, Grahame-Smith DG, Hallis KF, Hibble A, Wigley F. Aronson JK, et al. Br J Clin Pharmacol. 1977 Apr;4(2):213-21. doi: 10.1111/j.1365-2125.1977.tb00697.x. Br J Clin Pharmacol. 1977. PMID: 861136 Free PMC article.
• Plasma digoxin concentration--its relation to digoxin dosage and clinical effects in patients with atrial fibrillation.

  Redfors A. Redfors A. Br Heart J. 1972 Apr;34(4):383-91. doi: 10.1136/hrt.34.4.383. Br Heart J. 1972. PMID: 5020715 Free PMC article. No abstract available.
• Changes in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation.

  Ford AR, Aronson JK, Grahame-Smith DG, Carver JG. Ford AR, et al. Br J Clin Pharmacol. 1979 Aug;8(2):125-34. doi: 10.1111/j.1365-2125.1979.tb05810.x. Br J Clin Pharmacol. 1979. PMID: 486289 Free PMC article.
• Role of serum digoxin assay in patient management.

  Selzer A. Selzer A. J Am Coll Cardiol. 1985 May;5(5 Suppl A):106A-110A. doi: 10.1016/s0735-1097(85)80469-1. J Am Coll Cardiol. 1985. PMID: 3886746 Review.
• Is there a role for digoxin in atrial fibrillation without heart failure?

  Master J, Schweitzer P. Master J, et al. Cardiol J. 2009;16(5):483-6. Cardiol J. 2009. PMID: 19753533 Review.